The life science group Sartorius is launching an integrated system for the production and quality control (QC) of autologous cell therapies.
Sartorius has collaborated with ElevateBio, a cell therapy CDMO, among other partners, to test the Eveo platform.
Pharmaceutical companies are shifting from the development of autologous cell therapies to allogeneic cell therapies.
THE WOODLANDS, Texas and HUMMELSTOWN, Pa., March 17, 2026 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced a ...
Green Elephant Biotech announces the market introduction of Archimedes® One, the first system in a new category called the Dynamic Adherent Bioreactor. The company is introducing the platform to the ...
Zacks Investment Research on MSN
IBRX stock jumps on progress in NK cell therapy production
Shares of ImmunityBio IBRX rose more than 7% on Friday after the company announced that it completed two manufacturing ...
Quintessence's technology is designed to simplify the bio-separation process in CGT manufacturing while reducing production costs.
For years, one of the most powerful weapons against certain blood cancers, called CAR-T cell therapy, has required an ...
Researchers have developed a new method for monitoring iron flux - the movement and rate at which cells take in, store, use and release iron - in stem ...
The "Cell and Gene Therapy Manufacturing Market -- Growth, Share, Opportunities & Competitive Analysis, 2024 -- 2032" report has been added to the Credence Research Inc. offering. The global Cell and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results